Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Most I have seen update before December 2020 specifically Cigna - I seen addendums in January 2020, where Vascepa had changes to coverage. Sure update dates vary for insurance carriers across the board.
This drug list was updated in October 2020. For more recent information or other questions, please contact Cigna Customer Service,
at 1-800-668-3813 or, for TTY users, 711, 7 days a week, 8 a.m. – 8 p.m. local time, or visit www.CignaMedicare.com. The Formulary,
pharmacy network, and/or provider network may change at any time. You will receive notice when necessary. Cigna-HealthSpring is contracted with Medicare for PDP plans, HMO and PPO plans in select states, and with select State Medicaid programs. Enrollment in Cigna-HealthSpring depends on contract renewal.
HPMS Approved Formulary File Submission ID 20085, Version Number 18 I
Plans covered
Cigna-HealthSpring Alliance (HMO)
Cigna-HealthSpring Preferred (HMO)
Cigna-HealthSpring Preferred (PPO)
Cigna-HealthSpring Preferred GA (HMO)
Cigna-HealthSpring Preferred Part B Savings (HMO)
Cigna-HealthSpring Preferred Plus (HMO)
Cigna-HealthSpring Premier (HMO-POS)
Cigna-HealthSpring True Choice (PPO)
Cigna-HealthSpring True Choice Plus (PPO)
Way to many shares - take 100-150 million buy back 30-40 million shares while deflated share price is well below offering price.. This would give back share holder value by raising the EPS with increased earnings.
Well he's it least allowed one!
J.T. Speaking snip-it - let me know if I missed any you know's why is an accountant representing this company.
Louise Chen
How has the U.S. opportunity for VASCEPA unfolded? Has COVID-19 impacted sales this year? Can you discuss what revenues look like today and where they could grow to? And what size sales force do you have promoting VASCEPA in the U.S.? And how has reimbursement been for the drug?
John Thero
So as a cost effective drug, and you know, has been deemed even by the, you know, sort of [watchdog groups] to be cost effective and argue that we could significantly increase our price, but still be cost effective. You know managed care has provided good coverage for VASCEPA. It's continued to improve and expand that coverage, you know, throughout this year where, you know, for most plans, it's covered. We've moved to Tier 2 unrestricted in most places and starting to increasingly show up as a preferred brand for, you know many payors.
Our biggest challenge is introducing this drug to physicians and the COVID-era part didn't help. We did launch this in January, in the first quarter of this year. We had greater than 100% growth year-over-year. You know, COVID then hit in March, in the second quarter of this year. We had to pull back on direct sales promotions. You know, we're now back in the field, but as you probably hear and with many other companies, you know, that continues to be, you know, somewhat limited.
We're seeing, you know, roughly 40% of our target physicians open to having, you know, sales representatives come into, you know, educate them at this point. A lot better than it was a quarter ago, I think each month it's getting better. But, you know, it's still somewhat limited. So we're growing; we can believe that with good reimbursement, you know, positive clinical results, recommendations from, you know, many leading, you know, medical societies that we can, you know, continue to grow the drug and it's really in its infancy. The new dynamic here of late is that, you know, there is likely to be in the United States, you know, a generic entry. There are multiple generics that are approved, none that have launched yet. There have been comments by, you know, some of them of having limited supply.
We will see over time, what supply, you know, they can garner. But at this point in time, our belief is that because this is a market that is in its infancy and because supply is likely to be limited, you know, by the generics at least for some period of time that we can grow the market and grow the market hopefully faster, you know, than what generics can supply the market with that increment accreting to Amarin. So, we're continuing to push forward on our education programs, on our market aware of this programs and happy to have a lot of support from medical societies [the key opinion leader] in that regard.
Louise Chen
Amarin made a number of presentations at the ESC meeting late this summer. These presentations included the EVAPORATE final results, information on the interim analysis conducted during REDUCE-IT and an evaluation of the applicability of REDUCE-IT in a French population with a fast MI data. What are the key takeaways and how is that data received by physicians at the conference?
John Thero
You know, so the European Society of Cardiology meeting, which is the largest cardiology meeting in the world, you know, had I think seven different presentations relative to VASCEPA and related trials around the VASCEPA, a lot of discussion of the product, you know, in that meeting. In the background, the European Society of Cardiology expanded its guideline recommendations for icosapent ethyl, which is VASCEPA.
You know, last year, you know, they and the European Atherosclerosis Society, you know, both included VASCEPA, you know, in their guidelines recommending the use of VASCEPA for, you know, patients with established cardiovascular disease or, you know, triglycerides and other risk factors similar to what we have in the U.S. label.
He was actually the smartest one in the company, walked out with millions. As they say laughing all the way to the bank.
The truth is: This has been a very bad long term investment. Any of a handful of stocks like Tesla, Apple and Netflix on and on have outperformed this dog over a ten year period by a long shot. Great drug though I'm still taking it.
Maybe a weak patent does apply here, J.Z. sold all his shares faster then anyone. He is the patent holder for most of them from what I remember.
I'm not worried, I bailed out around end of February and bought Tesla. I may buy with upcoming market expansion. This stock is dead right now.
BreakdownTTM12/31/201912/31/201812/31/201712/31/2016
Total Revenue 545,995 429,755 229,214 181,104 130,084
Cost of Revenue 119,713 96,019 54,543 44,952 34,363
Gross Profit 426,282333,736 174,671 136,152 95,721
Operating Expenses 445,183358,015 282,896 181,707 161,347
Generics and Patents are not the only problem. Spending is out of control.
Anyone who displays a Nazis symbol, does not represent America and should be beaten to near death, by any WWII Vet standing in the vicinity.
We lost 100's of thousands of soldiers extinguishing the Nazi Plague.
Hi North! I don't think this is a situation where plaque is breaking off and causing blood clots. This is a symptom (clotting) seen in young children, blood just coagulating for example in toes. It appears blood is just clotting/thickening in various places in the body. In addition the vessel walls are highly inflamed. Vascepa certainly could reduce symptoms. I believe I had COVID-19 but was not able to get test. I believe Vascepa help keep my symptoms mild. I had quite a few tough nights breathing. Sure did not feel like any flu I ever had. I plan on an antibody test at some time.
In a small study EPA reduced blood clotting in men, but not women. DHA had the reverse effect, reduced clotting in woman but not men. Interesting. Did Reduce-It trial draw any conclusions like his or effects on clotting?
It's pretty clear what he is doing now fits the scope of science and/or scientist.
He certainly qualifies.
sci·en·tist
a person who is studying or has expert knowledge of one or more of the natural or physical sciences.
Not Cigna. Yes possible UHC has not updated Formulary, they have always been behind the curve, our company dumped UHC after just a year with this company. BC/BS is up to date, they where more progressive from the beginning. The had no PA from the beginning with low copay.
Maybe you have a small time practice. PA are not that difficult to handle for most physicians it's part of the job, typically office staph handle it. Not sure what you are referring, regarding 500 cut off.
Actually quite a few have updated Formulary as of January 1, 2020 along with a PA that matches the label. I thought it was a show stopper CIGNA is in his group of insurance carriers, January 1, 2020 the copay dropped by $40 to $60 for me.
Agree 100% and it's going to show up in a big way during this pandemic.
My guess the low refill rate is because of Insurance copay's or no coverage. Please post a document with drop out rate and reason for dropping Vascepa. Refill rate this year should improve since coverage by insurance carriers is improving. The fact that Trug level >499 is no longer a barrier. I was in this boat the last couple of years off label prescription, which is no longer the case.
The loss of Affordable Care Act has put many Americans at risk of being uninsured whats left of it.
Thousands have burned up in fossil fuel cars over the years.
Yes just in the last hour or so climbed again. We are at around 2.3% death rate so far!
USA 215,003 New +26,473 Deaths 5,102 New +1,049
That's right way ahead of the curve, compared to the old dealerships.
USA 213,908 New Cases +25,378 Deaths 4,788 New+735
Stock Transactions for the last year. Ya got to admit these guys where not holding for the big bucks.
3/4/20 Thero John F
Chief Executive Officer Sale 200,000 15.99 – 15.99 2,480,441 $3.2 M
2/28/20 Kennedy Joseph T
General Counsel Exercise of Options 3,612 -- – -- 193,507 $--
Thero John F
Chief Executive Officer Exercise of Options 13,472 -- – -- 2,680,441 $--
Ketchum Steven B
Officer Exercise of Options 3,056 -- – -- 516,012 $--
Kalb Michael Wayne ...
Chief Financial Officer Exercise of Options 3,056 -- – -- 83,927 $--
Berg Aaron D.
Officer Exercise of Options 3,056 -- – -- 188,905 $--
2/25/20 Thero John F
Chief Executive Officer Exercise of Options 229,030 -- – -- 2,672,271 $--
Kennedy Joseph T
General Counsel Exercise of Options 61,394 -- – -- 189,895 $--
Ketchum Steven B
Officer Exercise of Options 51,948 -- – -- 514,462 $--
Berg Aaron D.
Officer Exercise of Options 51,948 -- – -- 187,355 $--
Kalb Michael Wayne ...
Chief Financial Officer Exercise of Options 51,948 -- – -- 82,369 $--
1/31/20 Kalb Michael Wayne ...
Chief Financial Officer Exercise of Options 67,734 -- – -- 55,861 $--
Berg Aaron D.
Officer Exercise of Options 41,734 -- – -- 160,993 $--
Thero John F
Chief Executive Officer Exercise of Options 315,367 -- – -- 2,533,365 $--
Kennedy Joseph T
General Counsel Exercise of Options 74,734 -- – -- 160,825 $--
Ketchum Steven B
Officer Exercise of Options 67,734 -- – -- 488,100 $--
1/3/20 Zakrzewski Joseph S
Director Exercise of Options 300,000 3.40 – 3.40 84,547 $1.0 M
Zakrzewski Joseph S
Director Sale 300,000 20.94 – 20.94 84,547 $6.3 M
12/16/19 Kalb Michael Wayne ...
Chief Financial Officer Sale 25,000 23.05 – 25.66 21,552 $584.0 K
Berg Aaron D.
Officer Sale 43,253 25.46 – 25.46 133,806 $1.1 M
12/16/19 Kalb Michael Wayne ...
Chief Financial Officer Exercise of Options 25,000 2.19 – 2.19 21,552 $54.8 K
Berg Aaron D.
Officer Exercise of Options 43,253 12.60 – 12.60 133,806 $545.0 K
Zakrzewski Joseph S
Director Exercise of Options 100,000 9.00 – 9.00 84,547 $900.0 K
11/19/19 Thero John F
Chief Executive Officer Sale 274,454 22.65 – 22.65 2,342,285 $6.2 M
11/12/19 Ekman Lars G
Director Sale 38,600 19.35 – 19.35 -- $746.8 K
Ekman Lars G
Director Exercise of Options 38,600 14.40 – 14.40 -- $555.8 K
11/11/19 Thero John F
Chief Executive Officer Sale 475,546 17.05 – 17.88 2,616,739 $8.1 M
11/5/19 Ekman Lars G
Director Sale 6,400 18.00 – 18.00 -- $115.2 K
Ekman Lars G
Director Exercise of Options 6,400 14.40 – 14.40 -- $92.2 K
10/28/19 Thero John F
Chief Executive Officer Exercise of Options 11,601 2.50 – 2.50 3,092,285 $29.0 K
10/7/19 Thero John F
Chief Executive Officer Award of Options 1,265,250 0.000 – 0.000 3,080,684 $0.0
Kennedy Joseph T
General Counsel Award of Options 199,500 0.000 – 0.000 125,723 $0.0
Ketchum Steven B
Officer Award of Options 199,500 0.000 – 0.000 453,969 $0.0
Berg Aaron D.
Officer Award of Options 199,500 0.000 – 0.000 133,806 $0.0
9/3/19 Ekman Lars G
Director Sale 91,016 15.01 – 15.01 -- $1.4 M
Ekman Lars G
Director Exercise of Options 91,016 3.06 – 5.58 -- $320.3 K
8/21/19 Thero John F
Chief Executive Officer Exercise of Options 191,997 1.02 – 2.50 2,324,911 $300.0 K
Thero John F
Chief Executive Officer Exercise of Options 180,396 1.02 – 2.50 2,313,310 $271.0 K
7/11/19 Stack David M
Director Exercise of Options 51,991 2.19 – 2.50 -- $121.0 K
Stack David M
Director Sale 51,991 22.28 – 22.28 -- $1.2 M
7/2/19 Berg Aaron D.
Officer Exercise of Options 98,814 2.50 – 2.80 36,351 $255.8 K
Berg Aaron D.
Officer Sale 98,814 20.46 – 22.64 36,351 $2.1 M
7/1/19 Kennedy Joseph T
General Counsel Sale 54,186 19.52 – 19.52 31,260 $1.1 M
Kalb Michael Wayne ...
Chief Financial Officer Sale 50,000 19.67 – 19.67 20,840 $983.3 K
Kennedy Joseph T
General Counsel Exercise of Options 27,244 1.40 – 3.80 31,260 $70.0 K
Kalb Michael Wayne ...
Chief Financial Officer Exercise of Options 50,000 2.19 – 2.19 20,840 $109.5 K
6/28/19 Thero John F
Chief Executive Officer Exercise of Options 37,500 -- – -- 2,132,914 $--
Kennedy Joseph T
General Counsel Exercise of Options 53,437 -- – -- 58,202 $--
6/24/19 Berg Aaron D.
Officer Exercise of Options 100,000 2.50 – 2.50 36,351 $250.0 K
Berg Aaron D.
Officer Sale 113,195 18.59 – 18.59 36,351 $2.1 M
6/18/19 Zakrzewski Joseph S
Director Sale 100,000 19.02 – 19.02 84,547 $1.9 M
Zakrzewski Joseph S
Director Exercise of Options 100,000 3.40 – 3.40 84,547 $340.0 K
5/31/19 Kennedy Joseph T
General Counsel Sale 27,229 17.92 – 17.92 31,260 $488.1 K
Kennedy Joseph T
General Counsel Exercise of Options 27,229 1.40 – 3.80 31,260 $69.9 K
5/29/19 Stack David M
Director Exercise of Options 33,799 3.21 – 3.21 -- $108.5 K
Stack David M
Director Sale 33,799 18.45 – 18.45 -- $623.5 K
5/17/19 Stack David M
Director Sale 13,174 18.00 – 18.00 -- $237.1 K
Stack David M
Director Exercise of Options 13,174 3.21 – 3.21 -- $42.3 K
5/1/19 Berg Aaron D.
Officer Exercise of Options 26,000 -- – -- 49,546 $--
4/30/19 Kennedy Joseph T
General Counsel Exercise of Options 27,230 1.40 – 3.80 31,260 $69.9 K
4/30/19 Ketchum Steven B
Officer Sale 9,541 18.67 – 18.67 354,492 $178.1 K
4/1/19 Ketchum Steven B
Officer Sale 9,542 20.05 – 20.78 354,492 $191.4 K
Kennedy Joseph T
General Counsel Sale 54,172 20.03 – 20.80 31,260 $1.1 M
Ketchum Steven B
Officer Exercise of Options 9,542 1.40 – 2.95 354,492 $22.2 K
One day it will be OTC, years away. The generics will have a tough time with there vision of off label prescriptions. They have not even filed an ANDA with FDA yet. The FDA continues to struggle to catch up on ANDA approvals. Average time to approve: Three years. Three long years.
They have to make sure their bioequivelant drug can perform the same as Vascepa.
Here is a the FDA process.
ANDA Filing
AMRN, has been upgraded by Oppenheimer as a perform.
These analysts crack me up!
This company will be selling for sometime to come in U.S. big money. You would have to be crazy to sell after hours.
Probably a good idea, these sell offs usually bounce backup. Let's see what the big cheese has to say at 5:30. How this will actually effect sales.
Well a couple of weeks ago sold off AMRN around 80% of my holdings and but a REIT fund and Tesla. But ouch still hurts. WTF someone pay off the judge? Well this is one call I'm going to listen too.
case rate still rising! No sign of slow down yet.
USA 120,498 new cases today +16,372 deaths 2,008
Yea the FDA will scoff and dismiss this as a French trail. Kinda like they did with Jelis. What happened a few years later, they get egg on face after Reduce-It trial completed.
The FDA needs to be reformed scientist's need more power and say over at this agency.
Very true! I don't believe the U.S.numbers are close either. A lot of people ride out the virus at home and don't get tested.
We surpassed China Coronavirus cases.I do not consider this good news.
USA 81,943 +13,732 1,177
USA 81,943 +13,732 1,177
China 81,285 +67 3,287
Italy 80,589 +6,203 8,215
Spain 56,347 +6,832 4,154
Germany 43,646 +6,323 262
Iran 29,406 +2,389 2,234
France 29,155 +3,922 1,696
Switzerland 11,811 +914 191
UK 11,658 +2,129 578
S. Korea 9,241 +104 131
There has been some research in this area. Should be addressed with further trials.
EPA-Lung Tissue
Conclusion
EPA-preconditioned AD-MSCs increased secretion of pro-resolution and anti-inflammatory mediators (RvD1, PGE2, IL-10, and TGF-ß) by these cells. In CLP-induced sepsis, this was associated with further reductions in lung and distal organ damage, thus resulting in greater improvements in clinical score and higher survival rate, compared to therapy with nonpreconditioned AD-MSCs. This may be a promising therapeutic approach to improve outcome in septic patients.
Vascepa the perfect drug to reduce inflammation - COVID-9 causes inflammation in the lungs. How effective it is on this type of inflammation with a 4 Gram treatment, we may never know.
USA 80,275 New Cases +12,064 Death 1,153
Rate of infection increasing in U.S. not slowing yet.
10 Trails Listed at clinicaltrials.gov couple you might give your thoughts on.
COVID-19 Trials
Minneapolis-Trial?COVID-19-UofM
Looks like we surpass China tomorrow in cases. Not looking good, hope we start seeing a slow down - but not evident at this time.
Still early in the day.
USA 75,665 New Cases +7,454 Deaths 1,100